Reports Q1 revenue $0.5M vs. $0.6M last year. “We are extremely encouraged by our Q1 progress and believe that we are well positioned to meet our 2024 goals,” said CEO Dwight Egan. “Co-Diagnostics was pleased to announce the opening of our new manufacturing facility in Salt Lake and continued facility expansion in India, which will soon enable in-house Co-Primers, instrument, and test manufacturing at a low cost. We remain committed to delivering a 510(k) submission to the FDA for our new instrument and COVID-19 test kit in the near future and driving development of our TB, multiplex respiratory, and HPV tests throughout the remainder of the year”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
- Co-Diagnostics appoints Richard Abbott as president
- Co-Diagnostics CEO Dwight Egan delivers manufacturing, commercialization update
- Co-Diagnostics Inc Welcomes Richard Abbott as New President
- Co-Diagnostics price target lowered to $2.50 from $3 at H.C. Wainwright
